摘要
目的探讨比较聚乙二醇干扰素α-2a与重组人干扰素α-2b治疗慢性丙型肝炎的疗效,并对两种药品进行成本-效果分析.方法：将51例慢性丙型肝炎患者随机分为2组,一组用聚乙二醇干扰素,应用聚乙二醇干扰素a-2a联合利巴韦林片治疗;-组应用重组人干扰素α-2b联合利巴韦林片治疗,疗程48周.观察两组的生化指标,并进行成本-效果分析.结果：24周检测两组的HCV-RNA转阴率、ALT复常率值意义有统计学差异（χ^2=0.5,P〈0.05）,从12周和48周检查结果两组的HBV-RNA转阴率、ALT复常率值差异无统计学意义（χ ^2=0.5,P〉0.05）.α-2a组药品成本及成本效果显著高于α-2b组.结论：从丙肝的长期治疗考虑,选择重组人干扰素α-2b是一种更为经济的治疗方案.
Objective To investigate the effective of Peginterferonalfα-2a injection and recombinant human interferonα-2b injectionin the treatment ofchronic hepatitis C and to analyze their cost-effectiveness. Methods： 51 patient with chronic hepatitis C were selected and randomly divided into thetwo groups. One group was treated with peginterferonalfa-2a injection and ribavirin tablets. Another group was treated with Recombinant HumanInterferon α-2b Injection and Ribavirin Tablets. The course of treatment was 48 weeks. Biochemicalindexes were observed between the two groupsand the results were analyzed by the cost-effectiveness analytical methods. Results： There was significant difference （χ^2=0.5,P〈0.05） in the HBV-RNA negative conversion ratio and ALT normalization rate between the two group at week 24th .There was no significant difference （χ^2=0.5,P〉0.05） between the two group at week 12th and 48th. The cost and cost-effectiveness of the group α-2a was significant higher than the group ofα-2b.Conclusion： From the consideration of long-term treatment of chronic hepatitis C, recombinant human interferon α-2b injection should be a moreeconomical treatment plan.
出处
《药品评价》
CAS
2016年第10期27-29,共3页
Drug Evaluation
